Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Louisiana: - Mary Bird Perkins Cancer Center — Baton Rouge, Louisiana
- Mary Bird Perkins Cancer Center - Gonzales — Gonzales, Louisiana
Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Louisiana: - Louisiana Hematology Oncology Associates LLC — Baton Rouge, Louisiana
- Ochsner Hematology Oncology North Shore - Covington (West Region) — Covington, Louisiana
- Mary Bird Perkins Cancer Center - Metairie — Metairie, Louisiana
- University Medical Center New Orleans — New Orleans, Louisiana
- Ochsner Medical Center Jefferson — New Orleans, Louisiana
Phase 3 Recruiting Network
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation ther…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04423211
Sites in Louisiana: - LSU Health Baton Rouge-North Clinic — Baton Rouge, Louisiana
- Our Lady of the Lake Physician Group — Baton Rouge, Louisiana
Phase 3 Recruiting Network
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in Louisiana: - East Jefferson General Hospital — Metairie, Louisiana
- LSU Healthcare Network / Metairie Multi-Specialty Clinic — Metairie, Louisiana
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in Part 1 in combination with best supportive care (BSC) and in Part 2 wit…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07164443
Sites in Louisiana: - East Jefferson General Hospital — Metairie, Louisiana
Phase 3 Recruiting Academic/Other
This phase III trial tests whether high-dose vitamin D works in treating androgen-deprivation therapy (ADT)-induced bone loss in patients with prostate cancer who are undergoing androgen-deprivation therapy. Vitamins are substances that th…
Sponsor: University of Rochester
NCT ID: NCT05838716
Sites in Louisiana: - Louisiana State University Health Science Center — New Orleans, Louisiana
- University Medical Center New Orleans — New Orleans, Louisiana
- Ochsner Medical Center Jefferson — New Orleans, Louisiana
Phase 3 Recruiting Industry
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Sites in Louisiana: - Ochsner Clinic Foundation ( Site 0108) — New Orleans, Louisiana
Phase 3 Recruiting Industry
This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection of prosta…
Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
NCT ID: NCT07052214
Sites in Louisiana: - Southern Urology — Lafayette, Louisiana
- Ochsner Clinic Foundation — New Orleans, Louisiana
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in Louisiana: - Hematology/Oncology Clinic PLLC — Baton Rouge, Louisiana
- Louisiana Hematology Oncology Associates LLC — Baton Rouge, Louisiana
- Ochsner High Grove — Baton Rouge, Louisiana
- Northshore Oncology Associates-Covington — Covington, Louisiana
- Ochsner Medical Center Kenner — Kenner, Louisiana
Phase 2 Recruiting Network
This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation. Carboplatin is in a class of medications known as platinum-containing co…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05806515
Sites in Louisiana: - LSU Healthcare Network / Metairie Multi-Specialty Clinic — Metairie, Louisiana
- Louisiana State University Health Science Center — New Orleans, Louisiana
Phase 2 Recruiting Industry
Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of the main male sex hormone, testosterone in the body. Androgen receptor pathway inhibitors (ARPIs) are ano…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07005154
Sites in Louisiana: - Ochsner Health - Ochsner Medical Center - New Orleans — New Orleans, Louisiana
Phase 1 Recruiting Industry
The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.
Sponsor: AstraZeneca
NCT ID: NCT06879041
Sites in Louisiana: - Research Site — Metairie, Louisiana
Phase 1 Recruiting Industry
The study is to assess whether the Enolen is safe and delivers anti-androgen medication locally in patients that are planning for radical prostatectomy.
Sponsor: Alessa Therapeutics Inc.
NCT ID: NCT06257693
Sites in Louisiana: - Mary Bird Cancer Center — Metairie, Louisiana
Phase 1 Recruiting Industry
This is a first-in-human, open-label, multicenter phase 1 study to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of OP-3136, a lysine acetyltransferases 6A and 6B (KAT6A/B) inhibitor,…
Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT06784193
Sites in Louisiana: - University Medical Center - New Orleans — New Orleans, Louisiana
Phase 4 Recruiting Industry
The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred t…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05803941
Sites in Louisiana: - Tulane Cancer Center — New Orleans, Louisiana
- Ochsner Clinic Foundation — New Orleans, Louisiana
NA Recruiting Industry
To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients.
Sponsor: Axonics, Inc.
NCT ID: NCT06511141
Sites in Louisiana: - Louisiana State University — New Orleans, Louisiana
- WK Clinical Research — Shreveport, Louisiana
Recruiting Industry
The purpose of the registry is to evaluate real-world safety, efficacy, and patient reported outcomes among participants receiving Vanquish Water Vapor Ablation System therapy (Vanquish Therapy). This includes longitudinal assessment of pa…
Sponsor: Francis Medical Inc.
NCT ID: NCT07455058
Sites in Louisiana: - WK Advanced Urology Specialists — Bossier City, Louisiana